Advisors Asset Management Inc. Raises Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Advisors Asset Management Inc. grew its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 16.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 96,736 shares of the company's stock after purchasing an additional 13,668 shares during the quarter. Advisors Asset Management Inc.'s holdings in Novo Nordisk A/S were worth $11,518,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in NVO. Advisor OS LLC boosted its position in Novo Nordisk A/S by 0.6% during the 2nd quarter. Advisor OS LLC now owns 13,972 shares of the company's stock valued at $1,994,000 after acquiring an additional 82 shares in the last quarter. Cascade Financial Partners LLC raised its holdings in Novo Nordisk A/S by 2.3% in the 2nd quarter. Cascade Financial Partners LLC now owns 3,801 shares of the company's stock worth $543,000 after acquiring an additional 84 shares during the last quarter. Novare Capital Management LLC boosted its stake in Novo Nordisk A/S by 3.2% during the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company's stock valued at $325,000 after purchasing an additional 85 shares during the last quarter. AA Financial Advisors LLC increased its holdings in shares of Novo Nordisk A/S by 3.2% in the 2nd quarter. AA Financial Advisors LLC now owns 2,805 shares of the company's stock worth $400,000 after purchasing an additional 86 shares in the last quarter. Finally, Steel Grove Capital Advisors LLC raised its stake in shares of Novo Nordisk A/S by 2.3% in the second quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company's stock worth $541,000 after purchasing an additional 86 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO traded up $2.67 during trading on Wednesday, hitting $105.30. 7,517,325 shares of the company's stock were exchanged, compared to its average volume of 4,496,117. The business's 50-day simple moving average is $117.40 and its 200 day simple moving average is $129.27. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 52-week low of $94.73 and a 52-week high of $148.15. The company has a market cap of $472.51 billion, a price-to-earnings ratio of 33.22, a PEG ratio of 1.31 and a beta of 0.42.

Analyst Upgrades and Downgrades

NVO has been the topic of several research analyst reports. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, November 1st. Cantor Fitzgerald reiterated an "overweight" rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating for the company in a research report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.